Exelixis Inc. (EXEL)
Bid | 36.45 |
Market Cap | 10.35B |
Revenue (ttm) | 2.09B |
Net Income (ttm) | 503.03M |
EPS (ttm) | 1.76 |
PE Ratio (ttm) | 21.01 |
Forward PE | 15.12 |
Analyst | Buy |
Ask | 37.5 |
Volume | 2,437,692 |
Avg. Volume (20D) | 2,558,001.7 |
Open | 36.92 |
Previous Close | 37.18 |
Day's Range | 36.88 - 37.96 |
52-Week Range | 20.14 - 40.02 |
Beta | 0.57 |
About EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA...
Analyst Forecast
According to 18 analyst ratings, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $39, which is an increase of 5.45% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

4 weeks ago · businesswire.com
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase ProgramALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's...